
RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 08/8/7,547

Art Unit / Team No.: /654

Date Processed by STIC: 2/18/98

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,
- 2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

ARTI SHAH 703-308-4212

46

PAGE: 1

RAW SEQUENCE LISTING PATENT APPLICATION US/08/817,547

DATE: 02/18/98 TIME: 17:03:06

INPUT SET: S23504.raw

This Raw Listing contains the General Information Section and up to the first 5 pages.

Does Not Comply Corrected Diskette Needed 1 SEQUENCE LISTING 2 3 (1) General Information: 5 (i) APPLICANT: more way 6 -(A) NAME: Prof.Dr.Dr. Wolf-Georg Forssmann c/o NIP 7 (B) STREET: Feødor-Lynen-Str. 31 8 (C) CMY: Haphover (D) STATE: Niedersachsen Q English needed for a U.S. filing (E) COUNTRY: Germany 10 (F) POSTAL CODE: 30625 11 12 (ii) TITLE OF INVENTION (Peptide aus der Sequenz des hPTH (1-37) 13 14 15 (iii) NUMBER OF SEQUENCES: 36 16 (iv) CORRESPONDENCE ADDRESS: (Áv) COMPUTER READABLE FORM: 17 (A) ADDRESSEE: (B) STREET: (C) CITY: 18 (A) MEDIUM TYPE: Floppy disk (D) STATE: (E) COUNTRY: (F) ZIP: 19 (B) COMPUTER: IBM PC compatible 20 (C) OPERATING SYSTEM: PC-DOS/MS-DOS 21 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) Lesdingi AND responser are MANDATORY for a US felling. 22 (v) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION: 23 (2) INFORMATION FOR SEQ ID NO: 1: 24 25 (i) SEQUENCE CHARACTERISTICS: 26 27 (A) LENGTH: 10 amino acids 28 (B) TYPE: amino acid 29 (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown 30 31 32 (ii) MOLECULE TYPE: peptide 33 (iii) HYPOTHETICAL: no 34 35 36 (iv) ANTI-SENSE: no 37 38 39 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: 41 Ser Val Ser Glu Ile Gln Leu Met His Asn 42 43 10 44 45 (2) INFORMATION FOR SEQ ID NO: 2:

RAW SEQUENCE LISTING PATENT APPLICATION US/08/817,547

DATE: 02/18/98 TIME: 17:03:09

INPUT SET: S23504.raw

Thre segueres are correct.

47	(i) SEQUENCE CHARACTERISTICS:
48	(A) LENGTH: 9 amino acids
49	(B) TYPE: amino acid
50	(C) STRANDEDNESS: unknown
51	(D) TOPOLOGY: unknown
52	(5) 2020200
53 54	(ii) MOLECULE TYPE: peptide
55	(iii) HYPOTHETICAL: no
56	(to a large of the control of the c
57	(iv) ANTI-SENSE: no
58	
59	
60	
61 62	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
63	Ser Val Ser Glu Ile Gln Leu Met His
64	1 5
65	
66	(2) INFORMATION FOR SEQ ID NO: 3:
67	(-,
68	(i) SEQUENCE CHARACTERISTICS:
69	(A) LENGTH: 8 amino acids
70	(B) TYPE: amino acid
71	(C) STRANDEDNESS: unknown
72	(D) TOPOLOGY: unknown
	(D) TOPOLOGI: Unknown
73	/ii) Not Bout B. Bubb
74	(ii) MOLECULE TYPE: peptide
75	(111) INDOMINATOR
76	(iii) HYPOTHETICAL: no
77	(fact and any and any and any and any and any any and any
78	(iv) ANTI-SENSE: no
79	
80	
81	
82	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
83	
84	Ser Val Ser Glu Ile Gln Leu Met
85	1 5
86	
87	(2) INFORMATION FOR SEQ ID NO: 4:
88	
89	(i) SEQUENCE CHARACTERISTICS:
90	(A) LENGTH: 7 amino acids
91	(B) TYPE: amino acid
92	(C) STRANDEDNESS: unknown
93	(D) TOPOLOGY: unknown
94	\-\
95	(ii) MOLECULE TYPE: peptide
96	(11) Mondound 111 D. Peperde
97	(iii) HYPOTHETICAL: no
91 98	(III) HIPOTHEIICAL: NO
	(it) ANTI CONCO
99	(iv) ANTI-SENSE: no

RAW SEQUENCE LISTING PATENT APPLICATION US/08/817,547

DATE: 02/18/98 TIME: 17:03:11

INPUT SET: S23504.raw

```
101
102
103
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
104
105
           Ser Val Ser Glu Ile Gln Leu
106
           1
                           5
107
     (2) INFORMATION FOR SEQ ID NO: 5:
108
109
110
     (i) SEQUENCE CHARACTERISTICS:
                (A) LENGTH: 6 amino acids
111
                (B) TYPE: amino acid
112
113
                (C) STRANDEDNESS: unknown
                (D) TOPOLOGY: unknown
114
115
          (ii) MOLECULE TYPE: peptide
116
117
118
         (iii) HYPOTHETICAL: no
119
         (iv) ANTI-SENSE: no
120
121
122
123
      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
124
125
126
           Ser Val Ser Glu Ile Gln
127
           1
                            5
128
129
     (2) INFORMATION FOR SEQ ID NO: 6:
130
131
      (i) SEQUENCE CHARACTERISTICS:
132
                (A) LENGTH: 5 amino acids
133
                (B) TYPE: amino acid
                (C) STRANDEDNESS: unknown
134
                (D) TOPOLOGY: unknown
135
136
137
          (ii) MOLECULE TYPE: peptide
138
         (iii) HYPOTHETICAL: no
139
140
141
          (iv) ANTI-SENSE: no
142
143
144
145
      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
146
147
           Ser Val Ser Glu Ile
148
149
150
      (2) INFORMATION FOR SEQ ID NO: 7:
151
152
      (i) SEQUENCE CHARACTERISTICS:
```

RAW SEQUENCE LISTING PATENT APPLICATION US/08/817,547

DATE: 02/18/1 TIME: 17:03:1

INPUT SET: S23504.raw

```
153
                (A) LENGTH: 10 amino acids
                (B) TYPE: amino acid
154
155
                (C) STRANDEDNESS: unknown
156
                (D) TOPOLOGY: unknown
157
158
          (ii) MOLECULE TYPE: peptide
159
160
         (iii) HYPOTHETICAL: no
161
162
          (iv) ANTI-SENSE: no
163
164
165
166
      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
167
168
           His Asn Leu Gly Lys His Leu Asn Ser Met
169
170
171
      (2) INFORMATION FOR SEQ ID NO: 8:
172
      (i) SEQUENCE CHARACTERISTICS:
173
174
                (A) LENGTH: 9 amino acids
175
                (B) TYPE: amino acid
                (C) STRANDEDNESS: unknown
176
177
                (D) TOPOLOGY: unknown
178
179
          (ii) MOLECULE TYPE: peptide
180
181
         (iii) HYPOTHETICAL: no
182
183
          (iv) ANTI-SENSE: no
184
185
186
      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
187
188
189
           Asn Leu Gly Lys His Leu Asn Ser Met
190
                            5
191
      (2) INFORMATION FOR SEQ ID NO: 9:
192
193
      (i) SEQUENCE CHARACTERISTICS:
194
195
                (A) LENGTH: 8 amino acids
                (B) TYPE: amino acid
196
197
                (C) STRANDEDNESS: unknown
                (D) TOPOLOGY: unknown
198
199
          (ii) MOLECULE TYPE: peptide
200
201
202
         (iii) HYPOTHETICAL: no
203
204
          (iv) ANTI-SENSE: no
205
```

RAW SEQUENCE LISTING PATENT APPLICATION US/08/817,547

DATE: 02/18/98 TIME: 17:03:15

INPUT SET: S23504.raw

```
206
207
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
208
209
210
          Leu Gly Lys His Leu Asn Ser Met
211
212
     (2) INFORMATION FOR SEQ ID NO: 10:
213
214
215
     (i) SEQUENCE CHARACTERISTICS:
216
                (A) LENGTH: 7 amino acids
217
                (B) TYPE: amino acid
218
                (C) STRANDEDNESS: unknown
219
                (D) TOPOLOGY: unknown
220
221
         (ii) MOLECULE TYPE: peptide
222
         (iii) HYPOTHETICAL: no
223
224
225
         (iv) ANTI-SENSE: no
226
227
228
229
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
230
231
          Gly Lys His Leu Asn Ser Met
232
233
234
     (2) INFORMATION FOR SEQ ID NO: 11:
235
236
     (i) SEQUENCE CHARACTERISTICS:
237
                (A) LENGTH: 6 amino acids
238
                (B) TYPE: amino acid
239
                (C) STRANDEDNESS: unknown
240
                (D) TOPOLOGY: unknown
241
242
         (ii) MOLECULE TYPE: peptide
243
244
         (iii) HYPOTHETICAL: no
245
246
         (iv) ANTI-SENSE: no
247
248
249
250
     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
251
252
          Lys His Leu Asn Ser Met
253
          1
                           5
254
255
     (2) INFORMATION FOR SEQ ID NO: 12:
256
257
      (i) SEQUENCE CHARACTERISTICS:
258
                (A) LENGTH: 5 amino acids
```

SEQUENCE MISSING ITEM REPORT PATENT APPLICATION US/08/817,547

DATE: 02/18/98 TIME: 17:03:19

INPUT SET: S23504.raw

ADDRESSEE
STREET
CITY
STATE
COUNTRY
ZIP
CORRESPONDENCE ADDRESS
APPLICATION NUMBER
FILING DATE
CLASSIFICATION
CURRENT APPLICATION DATA
APPLICATION NUMBER
FILING DATE
PRIOR APPLICATION DATA

Application No.: 08/817,547

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: The General Information Section of the listing needs to be corrected. See attached.
Applicant Must Provide:	
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
	Rules Interpretation, call (703) 308-4216
	CRF Submission Help, call (703) 308-4212
For	PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE